Despite sharing some early symptoms, Alzheimer’s disease and late-life depression cause markedly different patterns of brain atrophy and chemical destruction. According to a new study published in the *Journal of Affective Disorders*, these findings could ultimately help doctors distinguish between the two conditions sooner.
Both Alzheimer’s disease and depression in older adults are very common and have puzzled clinicians for years because they tend to be similar in their early stages. Both can cause memory loss, low mood, and decreased motivation, making it difficult for doctors to distinguish between them and diagnose them accurately. Furthermore, depression in later life is an independent risk factor, approximately doubling the likelihood of developing Alzheimer’s disease later in life.
To better understand how these symptoms affect the brain, researchers sought to compare the structure and underlying chemistry of the brains of both patient groups. Previous studies have examined each condition separately, but have rarely made direct comparisons using both structural brain imaging and molecular profiling tools.
The team, led by Shuo Yang and Xuemei Wang from the Anhui Medical University Psychiatric Hospital in China, recruited 33 patients with Alzheimer’s disease, 38 patients with late-life depression, and 40 healthy older adults as a comparison group. All participants were over 60 years old and right-handed.
Participants underwent high-resolution brain MRI scans to map areas of gray matter contraction. The researchers then used specialized software tools to overlay these brain maps onto existing databases of neurotransmitter and cell type distributions, linking the reduced regions of the brain to specific chemical systems and cells.
Structural brain findings showed clear differences between the two conditions. Compared to healthy controls, Alzheimer’s patients showed widespread shrinkage in some of the brain’s most important memory centers, particularly the hippocampus and surrounding areas, as well as the cingulate cortex and a region called the precuneus, which is part of the brain’s default mode network.
When compared directly to the late-life depression group, Alzheimer’s patients showed even greater and more widespread atrophy, affecting large areas of the temporal, parietal, frontal, and occipital lobes. In contrast, the late-life depression group showed no statistically significant differences in brain volume compared to healthy controls.
Molecular analysis revealed something equally revealing. Both conditions disrupted the brain’s serotonin system, the chemical messenger most commonly associated with mood. Both groups also showed signs of impaired energy production at the cellular level, particularly involving mitochondria, the microstructures responsible for producing cellular energy.
However, beyond these common characteristics, the two conditions differed significantly. In Alzheimer’s disease, brain shrinkage is associated with a marked decrease in receptors for the cholinergic (acetylcholine) and dopaminergic (dopamine) systems, highlighting the characteristic synaptic loss in Alzheimer’s disease.
On the other hand, late-life depression showed a unique pattern in which brain shrinkage was associated with increased activity of dopamine and serotonin transporters, elevated levels of a specific glutamate receptor type (NMDA), and decreased blood flow to the brain. The researchers suggest that these patterns likely reflect functional impairment caused by chronic stress, rather than the irreversible neuronal death seen in Alzheimer’s disease.
Finally, the two conditions showed opposing patterns for a specific type of brain cell called a PVALB interneuron, which helps regulate brain activity. In depression, brain shrinkage correlated with the loss of these cells. However, in Alzheimer’s disease, brain shrinkage occurs in areas where these cells appear to cluster, perhaps reflecting an initial state of hyperexcitation as the brain attempts to compensate for toxic damage.
The authors summarize as follows: “AD and LLD exhibit ‘partially overlapping but markedly divergent’ profiles in gray matter atrophy patterns, neurotransmitter signatures, and cellular phenotypes, supporting the idea that the two diseases share common biological pathways but progress along different trajectories.”
However, there are some limitations. For example, the healthy control group was drawn from a publicly available dataset collected using different scanner equipment than the patient group, resulting in potential measurement discrepancies despite the researchers’ use of statistical correction techniques. Furthermore, when structural MRI scans are superimposed on a generalized chemical atlas, only correlations are visible. It is not possible to prove exactly what is going on in an individual patient’s brain.
The study, “Structural and molecular features of gray matter in Alzheimer’s disease and late-life depression,” was authored by Shuo Yang, Xuemei Wang, Yan Yan, Jianbo Zhang, Yuyue Wei, Dai Zhang, and Wenjun Yao.
